Navigation Links
Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer
Date:10/14/2008

Despite Widespread Use, Formulary Coverage of Targeted Cancer Therapies is

Inconsistent, According to a New Report from Decision Resources

WALTHAM, Mass., Oct. 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, of the many targeted cancer agents in Phase III clinical trials in the adjuvant setting, surveyed oncologists say that Genentech/Roche/Chugai's Avastin in early-stage colorectal cancer holds the most promise to achieve regulatory approval. Additionally, more than half of surveyed oncologists indicated that the minimum benefit that would persuade them to prescribe Avastin for early-stage colorectal cancer would be an 18 percent improvement in overall survival rates or a 21 percent improvement in disease-free survival rates.

The new Physician & Payer Forum report Targeted Cancer Therapies: The Shift from Metastatic to Early-Stage Disease. Clinician and Payer Attitudes finds that, in addition to Avastin, nearly all surveyed oncologists prescribe Genentech/Roche/Chugai's Herceptin, GlaxoSmithKline's Tykerb, Pfizer's Sutent and Bayer Healthcare/Onyx's Nexavar for their approved indications in cancer, which include breast cancer, non-small-cell lung cancer and renal cell carcinoma. The report finds that, while these agents have survival benefits, formulary coverage by managed care organizations (MCOs) of targeted cancer agents is inconsistent despite regulatory prescription drug plan guidelines that call for coverage of virtually all anti-tumor agents.

According to the report, MCO pharmacy directors commonly cite insufficient clinical benefit over cheaper alternatives as the reason for lack of reimbursement for targeted cancer therapies. Evidence has demonstrated that patients who have failed Herceptin in the metastatic setting should switch to Tykerb, and, according to National Cancer Institute guidelines, patients who fail Sutent could benefit from Nexavar. However, four of the MCOs that fail to cover Tykerb and six of the MCOs that fail to cover Nexavar cite the ability to negotiate a more favorable contract for a comparable drug. This suggests that some MCOs perceive Herceptin/Tykerb and Sutent/Nexavar as interchangeable agents.

"Marketers of Tykerb, Nexavar, and Sutent need to address the fact that some MCOs continue to perceive Herceptin/Tykerb, and Nexavar/Sutent as interchangeable, 'me too' agents," said Mary Argent-Katwala, Ph.D., director at Decision Resources. "Having only one from each of these pairings on a formulary leaves important clinical scenarios uncovered. We found that nearly one third of surveyed Medicare prescription drug plans carry neither Sutent nor Nexavar and one quarter fails to cover Avastin."

Targeted Cancer Therapies: The Shift from Metastatic to Early-Stage Disease. Clinician and Payer Attitudes is based on a U.S. survey of 100 oncologists and 20 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Decision Resources, Inc.

Christopher Comfort Elizabeth Marshall

781-296-2597 781-296-2563

ccomfort@dresources.com emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. News Media Advisory: Worlds Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments
2. Vermillion Receives Award From the Society of Gynecologic Oncologists
3. Oncologists Call For Medicare to Reconsider Anemia Drug Restrictions
4. NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
5. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
6. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
7. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
8. Symposium Highlights Yale Study Indicating Role of AHCC(R) for Immune System Enhancement and as a Promising Cancer Preventative
9. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
10. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
11. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... January 20, 2017 ... an Nothilfe   Die internationale humanitäre Stadt soll ... zu schaffen   Seine Hoheit Scheich ... VAE sowie Herrscher von Dubai , ... der Hilfe (International Humanitarian City IHC) zu verdreifachen, um ...
(Date:1/19/2017)... , Jan. 19, 2017 The global ... billion by 2025, according to a new study ... anticipated to be predominantly driven by high R&D ... the large-scale production of new and therapeutically advanced ... of drugs at an unprecedented rate into the ...
(Date:1/19/2017)... Jan. 19, 2017 The U.S. Food and Drug ... Idiopathic Constipation (CIC) in adult patients. "No ... disorders," said Julie Beitz , M.D., director of the ... Drug Evaluation and Research. "With the availability of new therapies, ... for their condition." ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica Graduate ... the electrifying line-up of events for its annual meeting “Coming Home 2017,” an ... “Coming Home 2017” will be held on Friday January 27 through Sunday, ...
(Date:1/21/2017)... ... January 21, 2017 , ... In the United States, 20 million ... freedom of recovery, they often feel shame for having struggled with an eating disorder ... In the workshop, “Rising Strong in Life After an Eating Disorder” -- to be ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... A new ... donate items they no longer use or need, from clothes to couches to dressers ... unwanted items and take them to the nearest Goodwill donation center through February 28th. ...
(Date:1/20/2017)... ... January 20, 2017 , ... Doctor C LLC, a company based ... ECRM trade show to continue the marketing and distribution of its product, The Right ... providing 400 percent better absorption than traditional vitamin C supplements. At the trade show, ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... to enhance people’s everyday lives, recently attended the January ECRM Trade Show in ... Science is known for its large range of supplements that keep the body ...
Breaking Medicine News(10 mins):